However, genetic deletion of CXCR3 or in vivo administration of anti-CXCR3 mAbs has been shown to enhance bone marrow NK cell infiltration, improving anti-myeloma efficacy [230] and promoting tumour rejection in melanoma models [231,232]. The gene discussed is CXCR3; the disease is plasma cell myeloma.